U.S. Markets closed

Radius Health, Inc. (RDUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.15-0.05 (-0.37%)
At close: 4:00PM EDT

12.15 0.00 (0.00%)
After hours: 4:00PM EDT

Radius Health, Inc.

950 Winter Street
Waltham, MA 02451
United States
617 551 4000

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees383

Key Executives

NameTitlePayExercisedYear Born
Mr. Jose CarmonaCFO & Treasurer639.05kN/A1972
Mr. Jesper HøilandSr. Advisor936.06kN/A1960
Dr. Charles Q. MorrisChief Medical Officer682.55kN/A1965
Mr. G. Kelly MartinCEO, Pres & DirectorN/AN/A1959
Dr. Stavros C. ManolagasFounder & Member of the Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; Guardant Health, Inc.; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Radius Health, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.